Axonics Modulation Technologies (NSDQ:AXNX) today said it received CE mark approval for its second-generation r-SNM implantable neurostimulator and wireless patient remote control. The r-SNM system is an implantable sacral neuromodulation device designed to treat urinary and bowel dysfunction. Irvine, Calif.-based Axonics previously won FDA approval for the device in April last year. Axonics’s r-SNM reduces how […]
Neuromodulation/Neurostimulation
ReCor Medical has positive renal denervation study news
ReCor Medical‘s renal denervation significantly reduced blood pressure among people with drug-resistant hypertension, according to a new study reported at the American College of Cardiology’s 70th Annual Scientific Session. The study news, announced yesterday, could suggest a turnaround in fortunes for renal denervation technology. One considered the next big thing in the medical device industry, […]
Axonics closes $201.3M offering
Axonics (NSDQ:AXNX) announced today that it closed a public offering of common stock worth proceeds of more than $200 million. Irvine, Calif.-based Axonics, which develops the Axonics r-SNM (sacral neuromodulation) system to treat bladder and bowel dysfunction, offered more than 4 million shares of its common stock at $50 per share, according to a news […]
Axonics announces $150M offering
Axonics (NSDQ:AXNX) announced today that it commenced a proposed public offering of common stock worth $150 million. Irvine, Calif.-based Axonics, which develops the Axonics r-SNM (sacral neuromodulation) system to treat bladder and bowel dysfunction, also expects to grant underwriters a 30-day option to purchase up to $22.5 million in additional shares of its common stock, […]
Axonics rises on mixed-bag Q1 results
Axonics (NSDQ:AXNX) posted first-quarter results that beat the revenue consensus on Wall Street but missed on earnings projections. The Irvine, Calif.-based company yesterday evening reported losses of –$22.5 million, or –57¢ per share, on sales of $34.4 million for the three months ended March 31 — versus a loss of –$14.6 million, or –43¢ per […]
Avanos Medical beats The Street in Q1 results
Avanos Medical (NYSE:AVNS) posted first-quarter results today that beat the overall consensus on Wall Street. The Alpharetta, Ga.–based company reported losses of -$7.6 million, or -16¢ per share, on sales of $180.7 million for the three months ended March 31, 2021 — versus a profit of nearly $4 million, or 8¢ per share compared with Q1 […]
Neuronetics ticks up before hours on mixed-bag Q1 results
Neuronetics (NSDQ:STIM) posted first-quarter results today that beat the revenue consensus on Wall Street and matched on earnings. The Malvern, Pa.-based company reported losses of -$7.9 million, or -31¢ per share, on sales of $12.3 million for the three months ended March 31, 2021, for a sales growth of 7.08% compared with Q1 2020. Earnings per […]
Neuroelectrics raises $17.5M Series A
Brain stimulation technology developer Neuroelectrics announced today that it raised $17.5 million in a Series A financing. Morningside Ventures led the funding round, the proceeds for which are earmarked for the development of Neuroelectrics’ non-invasive transcranial electrical stimulation (tES) platform. Cambridge, Mass./Barcelona, Spain-based Neuroelectrics plans to use funds to advance clinical trials for the platform […]
LivaNova rises on Street-beating Q1
LivaNova (NSDQ:LIVN) shares got a boost this morning on first-quarter results that beat the consensus forecast. LIVN shares were up 6.1% at $87.95 per share in early-morning trading today. The London-based company posted losses of -$29.7 million, or -61¢ per share, on sales of $247.6 million for the three months ended March 31, 2021, for […]
Neurostimulation may help restore arm function years after stroke
Stroke survivors who received vagus nerve stimulation (VNS) combined with rehabilitation had better arm and hand function, according to the results of a new study. In the international, multi-center clinical trial, 53 participants with moderate to severe arm weakness nine months to 10 years post-stroke received rehabilitation paired with VNS. Fifty-five patients within the same […]
Neurolutions wins authorization for stroke rehab device
The FDA announced today that it authorized the Neurolutions IpsiHand upper extremity rehabilitation system for stroke rehab. De novo authorization encompasses patients 18 years of age and older who are undergoing stroke rehabilitation to facilitate muscle re-education and need to maintain or increase their range of motion, according to a news release. It is a […]
